



## Change Order No. 6 – Work Order 23: ABAWD - Update MEDS Transactions for the 2023-2025 36-Month Rollover Process

### Purpose

The purpose of Change Order No. 6 – Work Order 23 is to outline the scope, timeframe, staffing, and costs to perform Quality Assurance (QA) reviews for system changes and functionality updates related to the ABAWD - Update MEDS Transactions for the 2023-2025 36-Month Rollover Process.

### Scope

ClearBest will conduct quality reviews of the delivered work products, services, and test outcomes related to the ABAWD - Update MEDS Transactions for the 2023-2025 36-Month Rollover Process and report findings monthly via Monthly Status reports. The scope of this effort includes:

1. Participation in meetings, discussions, and walkthroughs pertaining to Transitional Nutrition Benefits Recertification Hold (Auto), work products, and milestones.
2. Development of **Deliverable #1 - QA Monthly Status and Test Report (ABAWD – Update MEDS 36-Month Rollover)** based on the QA activities, findings, recommendations, issues, risks, mitigation strategies, and outcomes from the assessment of Accenture's, Deloitte's, and/or Gainwell's:
  - General and technical design, including participation in design discussions with State sponsors, the Consortium, development of System Change Requests (SCRs), and review and approval of SCRs via Change Control Board process
  - Developed enhancements
  - Testing of enhancements
  - Updates to job aids, online help, and web-based training
  - Management of the enhancement process from concept/design through implementation

Creation of QA assessment reports will be based on our approved approach and methodology identified in the ClearBest Deliverable #05 – DD&I Deliverable Review and Assessment Plan. To support the nature of the milestone-based SOWs, status and key findings will be included in the QA Monthly Status Report (ABAWD – Update MEDS 36-Month Rollover). The content of Deliverable #1 – QA Monthly Status and Test Report (ABAWD – Update MEDS 36-Month Rollover) will be incorporated into Deliverable #03 – QA Monthly Status Report.

3. Reporting on QA findings at the CalSAWS Weekly Status Meetings, Project Steering Committee (PSC), Joint Powers Authority (JPA) Board Meetings, and other stakeholder meetings as required.



### Staffing and Cost

To perform the QA Assessments of the ABAWD - Update MEDS Transactions for the 2023-2025 36-Month Rollover Process, work products/ deliverables as outlined above, ClearBest is assigning a part-time QA Business Analyst/Tester, and a part-time QA Technical Lead. The estimated effort for the ABAWD - Update MEDS Transactions for the 2023-2025 36-Month Rollover Process Statement of Work is as follows:

QA STAFF ROLE	MONTHS	HOURS	RATE	COST
QA Business Analyst/Tester	3	35	\$114	\$3,990
QA Technical Lead	3	35	\$139	\$4,865
<b>Total Cost</b>		<b>70</b>		<b>\$8,855</b>

### Costs by SFY

The cost schedules to support the ABAWD - Update MEDS Transactions for the 2023-2025 36-Month Rollover Process QA Services have been incorporated into the Quality Assurance Project Cost Schedules and are attached. The following provides the costs only by SFY:

DELIVERABLE	SFY 22/23
DEL #1 – QA Monthly Status and Test Report (ABAWD – Update MEDS 36-Month Rollover)	\$8,855
<b>Total</b>	<b>\$8,855</b>

### Work Order Approval

IN WITNESS WHEREOF, the Parties have set their hands hereunto as of the Execution Dates set forth below.

#### CalSAWS Consortium

By: \_\_\_\_\_  
Printed Name: Michael Sylvester  
Title: Board Chair  
Date: \_\_\_\_\_

#### ClearBest, Incorporation

By: \_\_\_\_\_  
Printed Name: Wendy Battermann  
Title: President  
Date: \_\_\_\_\_

#### CalSAWS Consortium

By: \_\_\_\_\_  
Printed Name: John Boule  
Title: Executive Director  
Date: \_\_\_\_\_



**APPROVED AS TO FORM:**

---

Jeff Mitchell  
Consortium Legal Counsel